2nd Quarter - Report

THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN for THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$54,630
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 20, 2017 $54,630 Replaced
2nd Quarter - Amendment Aug 11, 2017 $54,630 Replaced
2nd Quarter - Amendment Aug 11, 2017 $54,630 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

H.R.2810/S.1519, National Defense Authorization Act, matters related to breast cancer research.

LobbyistCovered position, as disclosed
KIMBERLY ANN BEER —

Contacted: Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC)

Bills named: S. 1519 (115th), H.R. 2810 (115th)

Budget/Appropriations BUD

Public Law 114-223: Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act, 2017, and Zika Response and Preparedness Act, issues related to cancer prevention and research funding. FY2018 Labor-HHS-Education Appropriations, issues related to cancer prevention and research funding.

LobbyistCovered position, as disclosed
KIMBERLY ANN BEER Legislative Assistant in the House of Representatives from 2005-2008

Contacted: Defense, Dept of (DOD); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

P.L.111-148, Patient Protection and Affordable Care Act, matters related to the Implementation of breast health education, research and clinical trials. H.R.1409, Cancer Drug Coverage Parity Act, advocate to require insurance companies cover iv-administered and orally-administered anti-cancer drugs at the same cost to patients. H.R.1628, American Health Care Act, advocate for inclusion of patient protections. H.R.930/S.497, Lymphedema Treatment Act, support Medicare coverage of certain lymphedema compression treatment items as durable medical equipment; H.R.1676/S.693, Palliative Care and Hospice Education and Training Act, support federal funding for research, training, education and awareness into palliative care; H.R.2307, Protecting Access to Lifesaving Screenings Act (PALS Act), advocate for continued access to and coverage for screening mammography; H.R.2999, Patients Access to Treatment Act, advocate for access to cancer therapies; S.1045, Save Womens Preventive Care Act, and S.689, Invest in Womens Health Act, protecting access to breast cancer screenings.

LobbyistCovered position, as disclosed
KIMBERLY ANN BEER —

Contacted: SENATE; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Defense, Dept of (DOD); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1676 (115th), S. 693 (115th), S. 1045 (115th), H.R. 1409 (115th), H.R. 1628 (115th), S. 497 (115th), H.R. 930 (115th), S. 689 (115th), H.R. 2999 (115th), H.R. 2307 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.